Share price close 16 Nov 2026
Quarterly or annual report filed
Quarterly or annual report filed
In one paragraph
Bristol Myers Squibb reported revenue of $48.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), down 0.2% from fiscal 2024. Net income was $7.05 billion and diluted earnings per share $3.46.
In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $13.1 billion, up 6.9% from a year earlier.
Figures from Bristol Myers Squibb's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026.
Against Health Care
Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.
Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.
| Product | Revenue | Share | Change |
|---|---|---|---|
| Legacy Portfolio | $21.79B | 45% | −15.4% |
| Opdivo | $10.05B | 21% | +8.0% |
| Orencia | $3.71B | 7.7% | +0.6% |
| Revlimid | $2.95B | 6.1% | −48.9% |
| Pomalyst/Imnovid | $2.73B | 5.7% | −22.9% |
| Other Growth products | $1.92B | 4.0% | +17.1% |
| Alliance and other revenues | $1.44B | 3.0% | −5.5% |
| Other lines (3) | $3.61B | 7.5% | — |
Bristol Myers Squibb beside the other S&P 500 members in Pharmaceuticals, by market value.
| Company | Market value | Day | 1 year | Revenue growth | Net margin | P/E |
|---|---|---|---|---|---|---|
| $128.5B | +1.8% | +29.2% | +4.2% | 18.5% | 13.9 | |
| $1.37T | +1.1% | +41.8% | +45.5% | 31.9% | 49.6 | |
| $686.1B | +0.8% | +47.0% | +7.8% | 16.2% | 42.6 | |
| — | +0.6% | +61.6% | — | — | — | |
| — | +0.2% | +11.7% | — | — | — | |
| — | +0.7% | +89.1% | — | — | — | |
| — | +1.0% | −30.9% | — | — | — |
Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.
Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.
| Revenue | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| United States | $29.21B | $31.50B+7.8% | $31.21B−0.9% | $34.10B+9.3% | $33.28B−2.4% |
| International | $16.32B | $13.82B−15.3% | $13.10B−5.3% | $13.20B+0.8% | $13.83B+4.8% |
| Other | $852.0M | $834.0M−2.1% | $699.0M−16.2% | $996.0M+42.5% | $1.09B+9.1% |
| Total revenue | $46.38B | $46.16B | $45.01B | $48.30B | $48.19B |
Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.43B | $20.78B | $22.56B | $26.14B | $42.52B | $46.38B | $46.16B | $45.01B | $48.30B | $48.19B |
| Revenue growth | +17.3% | +6.9% | +8.6% | +15.9% | +62.6% | +9.1% | −0.5% | −2.5% | +7.3% | −0.2% |
| Gross profit | $14.48B | $14.68B | $16.09B | $18.07B | $30.75B | $36.45B | $36.02B | $34.31B | $34.33B | $34.26B |
| Operating income | $6.08B | $5.33B | $5.11B | $5.91B | −$9.19B | $7.38B | $8.29B | $7.28B | −$7.49B | $10.00B |
| Net income | $4.46B | $1.01B | $4.92B | $3.44B | −$9.02B | $6.99B | $6.33B | $8.03B | −$8.95B | $7.05B |
| Diluted EPS | $2.65 | $0.61 | $3.01 | $2.01 | −$3.99 | $3.12 | $2.95 | $3.86 | −$4.41 | $3.46 |
| Gross margin | 74.5% | 70.7% | 71.3% | 69.1% | 72.3% | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% |
| Operating margin | 31.3% | 25.6% | 22.7% | 22.6% | −21.6% | 15.9% | 18.0% | 16.2% | −15.5% | 20.8% |
| Net margin | 22.9% | 4.8% | 21.8% | 13.2% | −21.2% | 15.1% | 13.7% | 17.8% | −18.5% | 14.6% |
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.06B | $5.28B | $7.07B | $8.21B | $14.05B | $16.21B | $13.07B | $13.86B | $15.19B | $14.16B |
| Capital expenditure | $1.22B | $1.05B | $951.0M | $836.0M | $753.0M | $973.0M | $1.12B | $1.21B | $1.25B | $1.31B |
| Free cash flow | $1.84B | $4.22B | $6.12B | $7.37B | $13.30B | $15.23B | $11.95B | $12.65B | $13.94B | $12.85B |
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.24B | $5.42B | $6.91B | $12.35B | $14.55B | $13.98B | $9.12B | $11.46B | $10.35B | $10.21B |
| Total debt | $6.57B | $7.96B | $8.60B | $50.30B | $53.67B | $50.36B | $44.61B | $44.34B | $53.03B | $49.12B |
| Shareholders' equity | $16.18B | $11.74B | $14.03B | $51.60B | $37.82B | $35.95B | $31.06B | $29.43B | $16.34B | $18.47B |
| Diluted shares | 1.7B | 1.7B | 1.6B | 1.7B | 2.3B | 2.2B | 2.1B | 2.1B | 2.0B | 2.0B |
| Dividends per share | $1.53 | $1.57 | $1.61 | $1.68 | $1.84 | $2.01 | $2.19 | $2.31 | $2.42 | $2.49 |
The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.
| Period | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.34B | $11.20B | $12.27B | $12.22B | $12.50B | $11.49B | $12.97B | $13.07B |
| Revenue, year on year | +7.5% | −5.6% | +0.6% | +2.8% | +1.3% | +2.6% | +5.7% | +6.9% |
| Gross margin | 61.0% | 72.9% | 72.5% | 71.9% | 67.2% | 70.2% | 71.3% | 68.3% |
| Operating income | $480.0M | $3.31B | $2.27B | $3.01B | $1.42B | $3.27B | $4.03B | $2.84B |
| Net income | $72.00M | $2.46B | $1.31B | $2.20B | $1.09B | $2.68B | $3.32B | $2.16B |
| Diluted EPS | $0.04 | $1.20 | $0.64 | $1.08 | $0.53 | $1.31 | $1.62 | $1.05 |
| Free cash flow | $4.06B | $1.69B | $3.56B | $5.99B | $1.60B | $757.0M | $3.09B | $3.84B |
The operating figures Bristol Myers Squibb reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.
| KPI | Latest | Period | Change on a year | Recent periods |
|---|---|---|---|---|
| International revenues | $4.0B | quarter to 30 Sep 2026 | up 2.6% | |
| Gross product sales | $18.0B | quarter to 30 Sep 2026 | down 20.1% | |
| Net product sales | $12.6B | quarter to 30 Sep 2026 | up 6.4% | |
| Growth Portfolio revenue | $7.7B | quarter to 30 Sep 2026 | up 11.7% | |
| Legacy Portfolio revenue | $5.4B | quarter to 30 Sep 2026 | up 0.9% | |
| Eliquis revenue | $4.7B | quarter to 30 Sep 2026 | up 25.2% | |
| Opdivo revenue | $2.4B | quarter to 30 Sep 2026 | down 6.2% | |
| Orencia revenue | $983.0M | quarter to 30 Sep 2026 | up 2.0% | |
| Yervoy revenue | $793.0M | quarter to 30 Sep 2026 | up 7.3% | |
| Reblozyl revenue | $750.0M | quarter to 30 Sep 2026 | up 22.0% | |
| Breyanzi revenue | $526.0M | quarter to 30 Sep 2026 | up 46.5% | |
| Alliance and other revenues | $463.0M | quarter to 30 Sep 2026 | up 24.5% | |
| Camzyos revenue | $420.0M | quarter to 30 Sep 2026 | up 41.9% | |
| Opdualag revenue | $367.0M | quarter to 30 Sep 2026 | up 22.7% | |
| Opdivo Qvantig revenue | $334.0M | quarter to 30 Sep 2026 | up 398.5% | |
| Revlimid revenue | $303.0M | quarter to 30 Sep 2026 | down 47.3% | |
| Zeposia revenue | $168.0M | quarter to 30 Sep 2026 | up 4.3% | |
| Pomalyst/Imnovid revenue | $130.0M | quarter to 30 Sep 2026 | down 80.7% | |
| Abecma revenue | $101.0M | quarter to 31 Dec 2025 | down 3.8% | |
| Sotyktu revenue | $100.0M | quarter to 30 Sep 2026 | up 25.0% | |
| Alliance revenues | $95.0M | quarter to 30 Sep 2026 | down 24.0% | |
| Sprycel revenue | $73.0M | quarter to 30 Sep 2026 | down 38.7% | |
| Abraxane revenue | $65.0M | quarter to 30 Sep 2026 | down 12.2% | |
| Krazati revenue | $58.0M | quarter to 30 Sep 2026 | up 9.4% | |
| Cobenfy revenue | $57.0M | quarter to 30 Sep 2026 | up 32.6% |
Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.
The same figures as plain text and JSON.
$48.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.
$7.05 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).
$3.46 for fiscal year 2025 (the twelve months to 31 Dec 2025).
71.1% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.
20.8% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.
$12.8 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.
In fiscal 2025, by product: Legacy Portfolio $21.79B (45%), Opdivo $10.05B (21%), Orencia $3.71B (7.7%), Revlimid $2.95B (6.1%), out of $48.19B in all, as stated in its annual report.
In the terminal